Marksans Pharma Q3 Results
- BSE: 524404
- NSE: MARKSANS
- ISIN: INE750C01026
- Sector: Biotechnology & Drugs
BSE
174.70
0.70 (0.40%)
0.70 (0.40%)Volume20.30 K
Updated: Wed 11 Mar, 2026 | 15:29:42
NSE
173
-1.06 (-0.61%)
-1.06 (-0.61%)Volume3.68 L
Updated: Wed 11 Mar, 2026 | 15:29:58
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q3 Results Highlights
- Total Income₹754.43 Cr.(10.64%)
- Operating Profit₹136.42 Cr.(15.53%)
- Profit After Tax₹113.20 Cr.(8.26%)
- Operating Margin18.08%(4.42%)
Note: Comparison is on YoY basis
Quarterly - Marksans Pharma Q3 Results
*All figures in crores except per share values
| Fiscal Period | Dec 25 | Sep 24 | QoQ Comp | Dec 23 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 618.01 | 525.75 | 2.52% | 475.11 | 9.62% |
| Depreciation/ Amortization | 24.33 | 19.51 | -9.62% | 22.00 | 17.59% |
| Operating Income | 136.42 | 116.17 | 16.02% | 111.02 | 15.53% |
| Net Income | 113.20 | 96.72 | 15.22% | 83.24 | 8.26% |
| Other Operating Expenses Total | 165.47 | 163.69 | 1.19% | 105.76 | 6.01% |
| Net Income Before Taxes | 150.62 | 124.60 | 12.97% | 112.66 | 5.14% |
| Total Revenue | 754.43 | 641.92 | 4.72% | 586.13 | 10.64% |
| Selling/ General/ Admin Expenses Total | 111.99 | 84.16 | 7.89% | 74.53 | 26.63% |
| Diluted Normalized EPS | 2.50 | 2.13 | 15.21% | 1.84 | 8.23% |